To analyze whether the treatment of cervical cancer cells with hydralazine and valproic acid is also able to increase their immune recognition, T lymphocytes derived from cervical cancer patients with HPV-16 or HPV-18 infection and with the HLA-A2 allele in their HLA Class-I haplotype, were stimulated with three known E6 and E7 HPV derived antigenic peptides, that specifically bind to the HLA-A*0201 allele [28-30]. This evidence concerns the gene HLA-A and cervical cancer.